Natera stock lifts 2026 outlook after 34% Q3 revenue growth

Published on 11/11/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock follows a stronger third quarter and a higher full-year outlook. A leadership change adds a new execution focus.

Growth and leadership transition

Third-quarter revenue rose 34.1% year over year as testing volumes increased.
Natera lifted its full-year revenue outlook after stronger oncology activity.
Solomon Moshkevich took over as chief executive, while Steve Chapman remains an adviser.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera reported stronger third-quarter operating momentum on Thursday, November 5, with revenue growth and higher testing volumes supporting a raised full-year outlook. The company also appointed Solomon Moshkevich as chief executive, effective immediately, as Steve Chapman stepped down from the role.

According to Natera's financial release, third-quarter revenue reached 794.0 million US dollars, compared with 592.2 million US dollars a year earlier. That represented growth of 34.1%. The company said the increase reflected higher volume and improvements in average selling prices.

Testing activity supports higher outlook

Natera processed 1,093,100 tests in the quarter, up 22.3% from 893,600 tests in the same period of 2025. Oncology testing was the strongest volume driver: approximately 339,500 oncology tests were processed, an increase of 60.9% year over year. Clinical molecular residual disease oncology units also increased by 32,700 from the second quarter.

Gross margin was 64.7%, compared with 64.9% a year earlier. Operating expenses rose 19.5% to 576.1 million US dollars, mainly because of headcount growth for new products and higher clinical trial expenses. The company nevertheless reduced its operating loss to 68.3 million US dollars from 97.6 million US dollars. Net loss narrowed to 59.9 million US dollars, or 0.42 US dollars per diluted share, from 87.5 million US dollars, or 0.64 US dollars per share.

Natera raised its 2026 revenue guidance by 140 million US dollars at the midpoint. The new range is 3.005 billion to 3.035 billion US dollars, compared with the previous range of 2.850 billion to 2.910 billion US dollars. Management continues to expect a gross margin of approximately 64% to 66%, while forecasting positive cash flow for the year.

New CEO takes over at Natera

Natera said Solomon Moshkevich became CEO and joined the board on November 5. Moshkevich joined the company in 2011 and most recently led its clinical diagnostics business. Chapman will remain a consultant and adviser to the board, providing continuity during the transition.

The combination of higher oncology volumes, increased research spending and a new chief executive leaves investors focused on execution. Natera's outlook assumes continued volume growth and stable average selling prices, while the company's expense plans show that it is continuing to invest in product development, clinical trials and commercial capacity.

Natera stock traded at 283.95 euros on Lang & Schwarz at 14:07 CET on Wednesday, November 11, 2026.